Amphipathic Octenyl‐Alanine Modified Peptides Mediate Effective siRNA Delivery
Journal of Peptide Science · 2025-10 · 31 (10)
DOI: 10.1002/psc.70054 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Peptide Science, online erschienen am 07.09.2025. Verfasst von Tõnis Lehto und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Technology, University of Tartu, Tartu, Estonia. Hauptthemen laut MEDLINE: Alanine, RNA, Small Interfering, Peptides, Nanoparticle Drug Delivery System. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Horizon 2020 Framework Programme, Swedish Foundation of Strategic Research FormulaEx, HORIZON EUROPE European Research Council.
Abstract (Originalsprache)
The development of therapeutic small interfering RNAs (siRNAs) has lately gained significant momentum due to their ability to silence genes in a highly specific manner. The main obstacle withholding the wider translation of siRNA‐based drug modalities is their limited half‐life and poor bioavailability, especially in extra‐hepatic tissues. Consequently, various drug delivery systems (DDSs) have been developed to improve the delivery of siRNAs, including short delivery peptides called cell‐penetrating peptides (CPPs). In this study, we explore the potential of using alkenyl‐alanine modifications to enhance the siRNA delivery efficacy with CPPs. We demonstrate on hPep peptides that incorporation of alkenyl‐alanines enhances the encapsulation of siRNAs into stable nanoparticles and contributes to increased cellular uptake. Furthermore, we demonstrate that the lead peptide, hPep3, induces effective RNAi‐mediated gene silencing in a reporter cell model as well as on the disease‐implicated endogenous CD45 gene target. The biodistribution studies in mice show that the alkenyl‐alanines are systemically well tolerated, and employing such modifications in the peptide backbone improves siRNA delivery in several tissues, including extra‐hepatic sites. As demonstrated on hPep peptides, alkenyl‐alanines offer a simple yet robust way to enhance the delivery efficacy of CPPs and have the potential to advance siRNA therapeutics beyond the liver targets.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Technology, University of Tartu, Tartu, Estonia.
- Faculty of Medicine, Institute of Pharmacy, University of Tartu, Tartu, Estonia.
- Division for Biomolecular and Cellular Medicine, Department of Laboratory Medicine, Karolinska Institute, Stockholm, Sweden.
- Center for Hematology and Regenerative Medicine (HERM), Department of Medicine Huddinge, Karolinska Institute, Stockholm, Sweden.
- Center of Research and Strategic Studies, Lebanese French University, Erbil, Iraq.
ORCID-Profile: Tõnis Lehto, Helena Sork, Annely Lorents, Oscar P B Wiklander, Taavi Lehto
Förderung
- Horizon 2020 Framework Programme
- Swedish Foundation of Strategic Research FormulaEx
- HORIZON EUROPE European Research Council
- Cancerfonden
- Swedish Research Council
- Estonian Research Council
- Vetenskapsrådet
- Eesti Teadusagentuur
Zitieren
APA
Lehto, T., Isakannu, M., Sork, H., Lorents, A., Bazaz, S., Wiklander, O. P. B., Andaloussi, S. E., & Lehto, T. (2025). Amphipathic Octenyl‐Alanine Modified Peptides Mediate Effective siRNA Delivery. Journal of Peptide Science, 31(10). https://doi.org/10.1002/psc.70054
Vancouver
Lehto T, Isakannu M, Sork H, Lorents A, Bazaz S, Wiklander OPB, et al. Amphipathic Octenyl‐Alanine Modified Peptides Mediate Effective siRNA Delivery. Journal of Peptide Science. 2025;31(10). doi:10.1002/psc.70054
BibTeX
@article{Lehto2025,
author = {Lehto, Tõnis and Isakannu, Marit and Sork, Helena and Lorents, Annely and Bazaz, Safa and Wiklander, Oscar P B and Andaloussi, Samir El and Lehto, Taavi},
title = {Amphipathic Octenyl‐Alanine Modified Peptides Mediate Effective siRNA Delivery},
journal = {Journal of Peptide Science},
year = {2025},
volume = {31},
number = {10},
doi = {10.1002/psc.70054}
}
EUVIMED